Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 7, 2026
Sellas Life Sciences Group, Inc. (SLS)
A forensic read on Sellas Life Sciences Group, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Grey Zone
Financial health
4.4
Distress distance
Clean
Earnings quality
4
Forensic signals
-37.9%
ROE
$2.1B
Market cap
65.6%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Sellas Life Sciences Group, Inc. earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 4.4, placing it in the Grey zone. 4 forensic signals were flagged in its latest SEC filings, led by stock-based comp load.
What the filings flag
399% of rev
FY2023
Stock-based comp load.Stock-based compensation ran 399% of revenue in FY2023 — about $0.08 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count: holders gave up about 34.2% of the company a year, and that rate is not falling. That is the figure to weigh, not the share of free cash flow.
stopped
FY2018→FY2019
Shareholder returns — halted.Capital returns have STOPPED — $487,000 of buybacks + dividends in FY2018, but ~$0 in FY2019. A halt usually means the company is conserving cash.
-$95.2M
FY2023–FY2025
Cash burn vs. reported loss.Over FY2023–FY2025, the company reported a cumulative net loss of $95.1M against operating cash flow of -$95.2M. Cash burn ran heavier than the reported loss — something outside net income (working capital, a cash item not in the P&L) is consuming cash faster than the loss alone implies.
n/m (stock split)
FY2022–FY2025
Share count (stock split).Diluted share count changed +462% over the last 3 years to FY2025, but that includes a large one-time change around FY2024 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw +77.8%/yr figure isn't a real buyback/dilution read here.
Key fundamentals
Latest Revenue$525,000.00
Revenue Growth YoY+65.6%
Revenue CAGR (3yr)+172.5%
Net Margin-7112.4%
Return on Equity-37.9%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Sellas Life Sciences Group, Inc.'s actual 10-K/10-Q/8-K filings?